Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

AC Immune (ACIU) Enterprise Value (2017 - 2026)

AC Immune has reported Enterprise Value over the past 11 years, most recently at -$114.3 million for Q4 2025.

  • Quarterly Enterprise Value fell 246.48% to -$114.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$114.3 million through Dec 2025, down 246.48% year-over-year, with the annual reading at -$114.3 million for FY2025, 246.48% down from the prior year.
  • Enterprise Value was -$114.3 million for Q4 2025 at AC Immune, up from -$135.6 million in the prior quarter.
  • Over five years, Enterprise Value peaked at $78.1 million in Q4 2024 and troughed at -$125.9 billion in Q4 2021.
  • The 5-year median for Enterprise Value is -$123.7 million (2024), against an average of -$10.0 billion.
  • Year-over-year, Enterprise Value plummeted 59519.71% in 2021 and then skyrocketed 147.77% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$125.9 billion in 2021, then skyrocketed by 99.9% to -$127.2 million in 2022, then decreased by 28.41% to -$163.4 million in 2023, then skyrocketed by 147.77% to $78.1 million in 2024, then plummeted by 246.48% to -$114.3 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Enterprise Value are -$114.3 million (Q4 2025), -$135.6 million (Q3 2025), and -$166.3 million (Q2 2025).